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Introduction: we have tested the hypothesis that treatment with a mycobacterial preparation that modulates the antibody
response, would diminish restenosis in a rat angioplasty model.
Materials/Methods: male Sprague–Dawley rats were used. All immunisations were given subcutaneously. Group A
(control) received normal saline on days 0, 21, and 42. Group B received SRL172 on days 0, 21, and 42. Group C
received SRL172 on days 0, 21, and 42, and hsp65/Incomplete Freund’s on days 21 and 42. Group D received hsp65/
Freund’s on days 21 and 42. Right common carotid arteries were balloon-injured on day 63 using a standard technique
known to produce MIH and animals were sacrificed on day 77. For each carotid 6 m cross sections were cut from
paraffin blocks. Cross-sectional areas were measured by computerised planimetry.
Results: balloon injury resulted in MIH in all animals. Data represents mean±SEM for the percentage of area enclosed
within the internal elastic lamina occupied by MIH (% MIH); which for groups A, B, C, and D was 85±11, 24±3,
27±7, and 17±3 respectively. All the treatment groups had significantly less MIH when compared to the control group
but no statistically significant difference was found between any of the treatment groups.
Conclusions: this is the first report that immunomodulation with mycobacterial material suitable for use in man, can
reduce MIH. Since such modulation has low risk, this raises the prospect of an important new therapeutic modality to
combat restenosis.
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Introduction may be diminished nitric oxide (NO) production by
damaged endothelial cells, and several strategies that
Since its initial introduction, percutaneous trans- augment local NO release have beneficial effects on
luminal angioplasty has become a successful and restenosis in animal models.9
widely used treatment for patients with atherosclerotic The endothelial injury caused by angioplasty may
disease in both the peripheral and coronary cir- be exacerbated by the host immune response to heat
culation.1 However, restenosis after technically suc- shock proteins (hsp). Hsps are proteins produced by
cessful percutaneous transluminal angioplasty occurs stressed cells which have been implicated in the patho-
in 25–30% of patients, limiting its long term effi- genesis and the pathophysiology of various immuno-
cacy.2,3 Restenosis is usually due to myointimal hyper- logical disorders including atherosclerosis.10 It is likely
plasia (MIH) and the histologic appearance is in- that they will be present on endothelial and smooth
dependent of both the type and the location of vascular muscle cells in the region of an angioplasty. In effect
injury. The key initiating event appears to be vessel the hsp acts as an autoantigen which can then be
wall injury resulting in loss of endothelium and the attacked by the immune system. In the vascular system
production of cytokines and growth factors which this situation can be induced experimentally by im-
produce a phenotypic change in the underlying vas- munising with a cross-reactive mycobacterial hsp
cular smooth muscle cells (VSMC).4–8 A key factor (hsp65) which leads to endothelial damage in rabbits
and mice.10,11 The effect appears to be dependent on
IL-4 secreted by Th2 (T-helper cell type 2) lymphocytes,∗ Please address all correspondence to: G. Stansby, Northern Vas-
cular Unit, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, U.K. and is probably mediated by antibody to the hsp.11,12
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The relevance of these observations to man is sug- SRL172 (Mycobacterium vaccae)
SRL 172 (heat-killed suspension of Mycobacterium vac-gested by the ability of affinity-purified human anti-
body eluted from hsp65 columns to damage stressed cae) was obtained at 10 mg/ml (SR Pharma, U.K.) in
vials of 0.3 ml. Each vial was diluted with 2.7 ml ofhuman endothelial cells in vitro.12
We have therefore tested the hypothesis that treat- sterile normal saline to produce a suspension of 1 mg/
ml. Vaccination consisted of 100 l containing 0.1 mgment with an appropriate mycobacterial preparation
might alleviate restenosis via two related mechanisms; per rat.
downregulation of IL-4 release, and modulation of the
cross-reactive antibody response to hsp. The myco-
bacterial preparation selected (SRL172) potently down-
Carotid balloon injuryregulates pre-existing Th2 responses.13 SRL172 is a
heat-killed preparation of Mycobacterium vaccae
In anaesthetised male Sprague–Dawley rats(NCTC11659).
(400–500 g), the right common carotid artery was de-
nuded of endothelium by the intra-luminal passage of
a 2-Fr arterial embolectomy catheter (BVM Medical
Limited, Leicester, U.K.), introduced through the leftMaterials/Methods
external carotid artery.5 Briefly, rats were anaesthetised
with intramuscular injections of xylazine hydro-All experimentation was conducted in accordance with
chloride (Bayer, Suffolk, U.K.) and ketamine hydro-the Animals (Scientific Procedures) Act 1986, and all
chloride (Pharmacia & Upjohn Limited, Crawley,surgical procedures were performed in accordance
U.K.). The ventral neck area was then shaved andwith the guidelines of the U.K. Home Office. Carotid
prepped with aqueous povidone-iodine solutionballoon injury was performed in adult male Sprague–
(Seton Healthcare Group plc, Oldham, U.K.). UnderDawley rats (400–500 g). The rats were housed in an
aseptic conditions, using a dissecting microscope withenvironmentally controlled facility on a light/dark
5× magnification, and with the use of micro-surgical(12/12 h) cycle and received standard laboratory chow
set, through a midline neck incision extending from(Special Diet Services, Essex, U.K.) and water ad libitum,
the mandible to the sternum, and after separation ofexcept in the immediate (2 h) postoperative period.
the strap muscles in line with the skin incision, theThe animals were divided into four groups (10 rats
ipsilateral sternocleiodomastoid muscle was removedin each). All inoculations were administered sub-
with cautery. The external and common carotid arteriescutaneously (s.c.); saline and hsp65 emulsified in in-
were then exposed, and a fine teflon sling passedcomplete Freund’s adjuvant were injected s.c. to the
under the external carotid artery. 7/0 ties (Ethicon,dorsal neck area, and SRL172 injections were given to
Edinburgh, U.K.) were applied to the distal externalthe base of the tail. Group A (positive control) received
carotid artery, and a clip applied to the proximal100 l of normal saline on days 0, 21, and 42. Group
external carotid artery. After arteriotomy with micro-B received 100 l of a suspension of SRL172 on days
scissors, the lumen of the external carotid artery was0, 21, and 42. Group C received 100 l of SRL172 on
flushed with heparinised-saline. A 2-Fr arterial em-days 0, 21, and 42, and 100 l (50 g) of hsp65 in
bolectomy catheter was then introduced into theincomplete Freund’s adjuvant on days 21 and 42.
lumen, and with controlled release of the proximalGroup D received 100 l (50 g) of hsp65 in incomplete
clip, it was passed proximally to the common carotidFreund’s adjuvant on days 21 and 42. In all animals,
artery. The balloon catheter was then tied loosely incarotid balloon injury was then performed on day 63,
place with 7/0 sutures. The catheter was then passedand the animal sacrificed on day 77.
three times with the balloon distended with 0.3 ml of
air to generate slight resistance, and with the common
carotid artery visibly distended. The balloon catheter
was then removed, and the proximal external carotidMaterial for injections
artery ligated. Hemostasis was secured with cautery
and wound closed in layers with 3/0 vicryl sutureshsp65/Freund’s
One hundred g of hsp65 (M. bovis HSP65 kDa: batch (Ethicon, Edinburgh, U.K.) to subcutaneous tissues
and to skin. The animals were then placed in a warmMA18, GBF, Germany) dissolved in 100 l of PBS (PBS
Dulbecco’s, GibcoBrl, Paisley, Scotland) was emulsified room and observed until full recovery.
At 14 days post-balloon injury (on day 77), thewith 100 l of incomplete Freund’s adjuvant (Sigma,
Steinheim, Germany). animals were sacrificed by an overdose of anaesthetic
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MIH in all animals. In contrast no MIH was detected
in the un-angioplastied contralateral common carotid
artery (data not shown). Results, expressed as the
mean±SEM for the percentage of MIH (% MIH) were
85±11, 24±3, 27±7, and 17±3 for groups A, B, C,
and D respectively. Group A had significantly greater
MIH when compared with Group B, C and D (p=0.007,
0.003, 0.001 respectively), and no statistical significant
differences exist between Groups B, C and D. (Fig. 1).
Fig. 1. MIH expressed as percentage area of MIH to the total area Discussionenclosed by the internal elastic lamina.
MIH is a lesion consisting principally of VSMCs whichagent. The neck wound was reopened, and both carotid
have migrated from the media to the intima andarteries were dissected free (together with harvest of
proliferated there. To produce MIH VSMCs need tothoracic aorta, through a ventral stenotomy). The entire
transform from a quiescent phenotype to one whichlength of the common carotid artery extending from
is migratory, proliferative and secretory. Damage tothe aortic arch to the carotid bifurcation was removed.
the endothelium is thought to be a central event inThe vessels were flushed with heparinised saline and
initiating these changes and indeed MIH seems to bethen placed in 10% formalin-saline. All tissues were
a universal response of blood vessels to endothelialprocessed for paraffin wax embedding. For each
damage. It complicates approximately 25–30% of an-sample, six 5 micron cross sections were cut from
gioplasties and vein bypass grafts and as such rep-paraffin blocks and stained with haematoxylin and
resents the major cause of angioplasty and vein grafteosin (H&E), and mounted on glass slides.
failures.4–8 It is a relatively rapid phenomenon, de-Planimetric measurements were made directly from
veloping maximally by 14 days in the rat carotid andthe slide with two independent blinded observers
usually within 3 months clinically.5 In this it is unlikeper section, using an interactive computerised image-
atherosclerosis which usually takes many years toanalysis system (Seescan Biological Applications).
develop.The ratio of the area of MIH to the total area enclosed
There is considerable evidence to suggest that theby the internal elastic lamina (IEL) was calculated.
cytokines secreted by T-cells can modulate the patho-This was then expressed as a percentage to represent
logical cellular events that occur in the developmentthe portion of the lumen occupied by the myointimal
of atherosclerosis, where there is also VSMC migrationhyperplastic change14 (Fig. 1).
and proliferation.15,16 However, the role of the T-cell inResults were expressed as the mean±SEM for the
MIH has been less well explored, although it has beenpercentage of MIH (% MIH). Analysis of variance was
demonstrated in an animal model that T lymphocyteperformed for multiple comparisons. Mann–Whitney
depletion results in larger proliferative lesions afterU-test was employed for inter-group comparisons, and
catheter denudation.17the Bonferoni correction factor was used for multiple
Recent studies in our laboratory have shown thatcomparisons where appropriate. A p value of less than
patients with atherosclerosis may have decreased Th10.05 was considered as a significant difference between
immunity as compared to age-matched controls.18the experimental groups.
Whether this decrease is in any way causal was not
clear. It did however lead us to postulate that the
inflammatory responses to vessel injury might be po-
tentially modifiable by altering the pattern of response.Results
We have tested this hypothesis in the model reported
here, and the reduction was substantial. If a similarAll animals survived the procedure but two died
subsequently and were unavailable for analysis. Sec- effect could be produced in human restenosis it could
have major therapeutic potential. Unfortunately, fortions from six animals were deemed unsuitable for
analysis due to poor orientation or thrombosis leaving technical reasons, we were unable to directly measure
the T-cell cytokine response in rats. However, SLR172eight carotids in group A, eight in group B, nine in
group C and seven in group D available for analysis. is known to downregulate Th2 responses in other
contexts.Injury to the common carotid artery had resulted in
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There has been much interest in the role that Th1 the inadequacy of the Th1/Th2 paradigm.31 Frostegard
et al.32 reported that cytokine expression in advancedand Th2 cytokines play in various other human dis-
eases such as tuberculosis, asthma, rheumatoid arth- human atherosclerotic plaques was dominated by Th1
cytokines such as IFN, with Th1 cytokines in 70% ofritis and a number of autoimmune conditions.19–21 Th1
cells produce IFN-, interleukin-2 (1L-2) and TNF. Th2 plaques using the sensitive method of PCR and in
30–50% using immunohistochemistry. Also in mousecells produce IL-4, IL-5, IL-6, IL-10 and IL-13.22 Both
types of T cell can cause cell-mediated inflammation, models of atheroma formation and transplant va-
sculopathy the neutralisation or genetic absence ofand both drive antibody formation, though different
immunoglobulin subclasses are involved, and the IFN markedly reduces the amount of VSMC related
thickening that occurs.33–37 Similarly, in the absence ofquanitity of antibody accompanying a Th2 response
is usually much greater. When regulation of Th1 re- leukocytes IFN can induce atherosclerotic changes in
mice by an action on VSMCs to promote mitogenesis.38sponses fails, Th1-mediated autoimmune diseases
such as multiple sclerosis can result.23 Dysregulated On the basis of these publications, downregulation of
IFN- release by hsp65 in oil, with or without a switchTh2 responses can lead to a variety of pathologies,
including allergic reactions, Th-2-mediated auto- to Th2, might be expected to be effective at limiting
MIH.immunity and also chronic fibrotic inflammation such
as that seen in idiopathic pulmonary fibrosis (IPF).24,25 In contrast, other studies have shown that IFN can
inhibit VSMC proliferation in vitro.31,39–43 Moreover,The existing literature suggests that endothelial
damage mediated by recognition of hsp involves anti- when infused into a rat carotid artery after balloon
catheter denudation injury, IFN significantly reducedbody and the antibody-stimulating Th2 cytokine IL-
4.11,12 Moreover patients with peripheral vascular dis- early smooth muscle cell replication and subsequent
MIH.44 Similarly inhibition of proliferation of VSMCsease have elevated levels of antibodies to hsp70.26,27 It
has been suggested that such antibodies may bind to by 30–70% was seen when the gene for IFN was
transfected into human endothelial cells co-culturedstressed endothelial cells, and may be a factor in
producing coronary artery disease after heart trans- with VSMCs.45 A protein has also been described which
is upregulated by IFN in vascular smooth muscleplantation.28 Mukherjee et al.29 showed no association
between preoperative antibody levels to hsp65 and cells and which is found to be downregulated in
areas of anastomotic MIH.46 In another study it wascoronary restenosis, but did show that those patients
where levels of such antibodies dropped after an- demonstrated that in histological studies of vein graft
MIH in rats, IFN was found only in isograft controls.gioplasty were less likely to restenose. In fact the role
of antibodies to hsp could be complex, because patients Downregulation of IFN appeared to accompany the
early cytokine response triggering MIH.47 Thus on thewith vascular disease have not only raised antibody,
but also raised levels of the hsp themselves.27 Thus an basis of this subset of publications, it might be expected
that shifting the T-cell response towards Th1, with aapparent fall in antibody levels may merely reflect an
increase in levels of the protein. Moreover the hsp resultant increase in IFN production, should prevent
MIH.have regulatory effects, and bind to arterial smooth
muscle cells, leading to enhanced survival wihout a Since the contrary conclusions can be drawn from
the literature, it seems clear that the Th1/Th2 paradigmrequirement for internalisation.30 Therefore the as-
sumption that the effect of antibody is to damage cells cannot by itself explain the pathogenesis of MIH.
Indeed there are numerous other disease models wherewhich have membrane-associated hsp may only be
part of the truth. Antibody may also block some the greatest immunopathology is seen when a mixture
of Th1 and Th2 cytokines is released into the lesion.48–50essential regulatory role of the hsp.
In the light of these findings, it was anticipated that The results obtained in this study indicate that Th1/
Th2 balance is also unable to explain the beneficialdownregulation of Th2 responses by SRL172 (which
contains mycobacterial hsp65) would limit MIH, effects of the mycobacterial products used. There are
two obvious unifying hypotheses, which are not mu-whereas hsp65 in oil (group D), which enhances Th2
responses, was expected to increase the MIH. However tually exclusive. First, it may be that SRL172 and hsp65
in oil are both able to alter the class or fine specificitythe results indicate that the initial hypothesis was too
simple, because both treatments were effective, and of the antibody to hsp, so as to terminate a directly
damaging effect, or relieve the blockage of a crucialremained effective when used together (Group C), so
a simple Th1/Th2 explanation is not possible. regulatory role of hsp. The second hypothesis is that
both treatments activate a class of regulatory cells thatAn assessment of the literature on the effects of the
Th1 cytokine IFN- on VSMC proliferation also reveals mediate a critical change in the pattern of cytokine
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